PMLS Virtual Series 2021 – Genomics & Precision Medicine

On Demand Now Click Here

April 27, 2021

9:57-10:00am EST

Welcome and Opening Remarks

Nigel Russell, Founder and President, Precision Medicine Leaders’ Summits, The Journal of Precision Medicine 

10:00-10:45am EST

Keynote – Leveraging Data from Clinical Trial Participants to Nation-scale Cohorts

Howard J. Jacob, PhD, Vice President, Head of Genomic Research and Head of Data Convergence, AbbVie 

Within Pharma, large genomic groups and a few big health systems large collections of patients/participants have hundreds of millions of data sets from real world data (insurance claims and electronic health records), population scale cohorts with whole genome sequencing or imputed whole genome and in some cases all these data on the same individuals. These data sets combined with computational biologists and large compute farms are identifying many variants of potential interest related to new targets, better disease definition, better understanding of disease mechanism, patient stratification and ultimately patient care.

10:50-11:50am  EST

Comprehensive Genomic Profiling: A New Standard of Care in Oncology

Moderator: Lauren Feldman, MHA, Vice President, Value, Access and Reimbursement, ADVI Health, LLC

Panelists: Suzanne Belinson, PhD, MPH, Vice President, Commercial Markets, Tempus; Trish Brown, MS, Director, AMR Payer Partner, Field Market Access Lead, Illumina; Rob Dumanois, Director, Reimbursement Strategy, Thermo Fisher Scientific

  • The landscape for comprehensive genomic profiling
  • The obstacles to coverage & reimbursement
  • Access to Comprehensive Genomic Profiling Coalition

11:55-12:45pm  EST

Factors Influencing the Acceptance of a Novel Diagnostic Technology in the Coverage Policy of a Health Care Plan: Case Study

Mark D. Hiatt, MD, MBA, MS, Vice President, Medical Affairs, Guardant Health; Eugean Jiwanmall, MBA, MPH, Senior Research Analyst, Medical Policy & Technology Evaluation, Independence Blue Cross

This case study of one plan’s evaluation and ultimate acceptance of liquid biopsy, in the context of ascertaining the genomic drivers of lung cancer, will illustrate the factors influencing such coverage decisions. Factors discussed include (a) published studies in support of the technology, (b) the description of the technology, and (c) the opinion of other plans and their intermediaries.

12:50-1:35pm      EST

Keynote – The Path to Preventive Genomics

Robert C. Green, MD, MPH, Professor of Medicine; Director, G2P Research Program; Associate Director for Research, Partners Personalized Medicine, Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Broad Institute and Harvard Medical School

It is now 20 years since the completion of the first draft of the Human Genome Project. While there have been enormous breakthroughs in diagnostics and biotechnology, the promise of using genomics to stratify risk and prevent human disease has not been realized. This presentation will summarize recent data from the MedSeq and BabySeq Projects which are the first randomized trials to assess medical, behavioral and economic impact of comprehensive sequencing in healthy adults and newborn infants, respectively. This presentation will also describe a new vision for clinical utility research in preventive genomics.

1:40-2:15pm      EST

Expanding Precision Medicine into Chronic Disease – An opportunity to act on Type 2 Diabetes Complications and Alzheimer’s Disease

Steve Gardner, PhD, Chief Executive Officer & Founder, Precision Life Ltd.

Steve will present the challenge of moving Precision Medicine beyond oncology and rare disease, and how combinatorial analytics enables high resolution patient stratification enables us to accurately identify insights that enable us to understand disease biology in the context of patients.  We will exemplify how we are using the approach to develop combinatorial risk scores that predict diabetes complications at diagnosis and finding new insights into Alzhiemer’s disease biology that have clinical and pharmaceutical relevance.

2:15pm      EST 

Closing Remarks

Nigel Russell, Founder and President, Precision Medicine Leaders’ Summits, The Journal of Precision Medicine